RankingsPricing
  1. US-listed companies
  2. TEVA PHARMACEUTICAL INDUSTRIES LTD
  3. Raw

TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA

Market cap
$27.8B
P/E ratio
SummaryFinancials
Back to summarized table
Dec 31,
2010		Dec 31,
2011		Dec 31,
2012		Dec 31,
2013		Dec 31,
2014		Dec 31,
2015		Dec 31,
2016		Dec 31,
2017		Dec 31,
2018		Dec 31,
2019		Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023		Dec 31,
2024
Net income (loss)3,3392,7681,9101,2533,0421,597311-16,449-2,472-1,000-4,099456-2,406-615-1,959
Impairment of goodwill------90017,1003,027-4,628-2,0457001,280
Impairment of long-lived assets and assets held for sale--------------1,275
Depreciation and amortization9771,0691,7081,6421,5081,3081,5242,1121,8421,7221,5571,3301,3081,1531,059
Net change in operating assets and liabilities253-597-414-968-290-967-1,219363,000,0001,8238962,1881,701-1,25772435
Deferred Income Taxes Net And Uncertain Tax Positions-199-500-690-1,380-22623715-2,331-837-985-696-120-1,059-317-634
Stock-based compensation8091826495117124133155119129119124121123
Net loss (gain) from sale of business and long-lived assets-723-18-1867641,0901918213-104-104122
Other items-----736---2810016-9161560
Net cash provided by (used in) operating activities4,1364,1344,5723,2375,1275,5425,2253,5072,4467481,2167981,5901,3681,247
Beneficial interest collected in exchange for securitized trade receivables--------------1,291
Purchases of property, plant and equipment and intangible assets-------------526498
Proceeds from Divestiture of Businesses-----------311686843
Purchases of investments and other assets--------1198554714671
Proceeds from sale of investments-----------1724-40
Acquisitions of businesses, net of cash acquired4,9516,561-393633,30936,148-43----7-15
Other investing activities-294993104305212282-11-58-24-1-5-2
Net cash provided by (used in) investing activities-5,455-7,601-1,134-1,147-1,450-5,565-35,7402,1641,8661,3558631,523656968792
Repayment of senior notes and loans and other long term liabilities1,9727512,2133,1338392,5219993,3007,4463,9441,8716,6491,3694,1521,641
Proceeds from Debt, Net of Issuance Costs--------4,4342,083-4,974-2,451-
Proceeds from short term debt----------550700-700-
Repayment of short term debt----------559700-700-
Purchase of shares from non-controlling interests---------------64
Dividends paid to non-controlling interests---------------78
Other financing activities-5523-9-178-169-74-57-11-5-6-118-212-8
Net cash provided by (used in) financing activities5733,336-1,678-3,883-2,3754,80525,217-5,750-3,351-1,926-1,885-2,172-1,487-1,913-1,791
Translation adjustment on cash and cash equivalents---------142168-128-123-30-174
Net change in cash, cash equivalents and restricted cash--------8191932022163639374
Beneficial interest obtained in exchange for securitized trade receivables--------------1,286
Dividend Declared To Noncontrolling Interests-------------67-
Interest--------8158408469139481,0781,004
Income Taxes Paid, Net3542766141,298675802341106420552709495543298471
Other current assets51-240-54106-3687-517658-1,437-1,416-1,473-2,271-828-1,525-1,104
Increase Decrease In Certain Current Liabilities Excluding Debt-295543-19378-614-12640-1,801-500643-4637641,9141,588258
Trade receivables net of sales reserves and allowances-3627049368571076334351488-394-293-57433412245
Inventories-16-762-5113992301293721992627141380-163-147166
Net Change In Items Comprising Supplemental Disclosure Of Cash Flow Information-2535974149682909671,219-363-1,823-896-2,188-1,7011,257-72-435